key: cord-0936458-4knoed41 authors: Ravindran, TK Sundari; Teerawattananon, Yot; Tannenbaum, Cara; Vijayasingham, Lavanya title: Making pharmaceutical research and regulation work for women date: 2020-10-27 journal: BMJ DOI: 10.1136/bmj.m3808 sha: ea2a883c5bdb53fb2d4599922dd3293aa52de51b doc_id: 936458 cord_uid: 4knoed41 The legacy of male bias within pharmaceutical research, regulation, and commercialisation needs to be rectified, argue Sundari Ravindran and colleagues New research on sex differences in disease pathology and outcomes demonstrate the need for a womenfocused approach. Other studies show the under-representation of women in some drug trials and the exclusion of females in preclinical phases. Members of the US Congress and House of Representatives make representations to the FDA. 2014: Beginning in October 2014, the national health research funding agency funds only experiments that use an equal balance of male and female cells or animalsunless a study explicitly and justifiably aims to investigate some sexspecific questions. [3] 2015: The FDA has been producing Drug Trial Snapshots since 2015. A Snapshot shows trial participants by sex, age, race/ethnicity for every newly approved medicinal product. [1] Analyses of effectiveness and toxicity by representative subgroup are not displayed. The Office of Women's Health launches the Diverse Women in Clinical Trial Initiative. The aim is to raise awareness about the importance of participation of diverse groups of women in clinical research. [1] 2018: A draft guidance to the industry is produced to include pregnant women in clinical trials. [4] CANADA 1997: The Government of Canada issued the 'Guidance Document on the Inclusion of Women in Clinical Trials,' recommending the inclusion of women of childbearing as well as post-menopausal years in all phases of clinical trials. The sample sizes were to be large enough to enable the evaluation of sex differences in treatment effects. [5] Guidance only. Not enforced. 1997-2013: Studies report better representation of women in third phase clinical trials, but not so in phases 1 and 2, or for pregnant and lactating women; poor representation of females in preclinical phases are also reported. [6] 2009: The Health Portfolio of the Government of Canada updates its sex and gender-based analysis (SGBA) policy. This states that SGBA must be applied to the development, implementation, and evaluation of the Health Portfolio's research, legislation, policies, programs, and services to address the different needs of women and men. 2013: Based on emerging evidence, an updated version of the Guidance Document, 'Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences,' was released, superseding the 1997 document. This version provided advice to researchers on analysis of sex differentials in drug safety and efficacy, and guidance for managing inadvertent pregnancy in trial participants as well as the safe inclusion of pregnant and breastfeeding women. [6, 7] 2019: Health Canada establishes a Scientific Advisory Board on Health Products for Women to review practices aimed at preventing further occurrences of market withdrawal of medical products that harm women. [8] EUROPEAN COMMISSION 2014: The EU Clinical Trial Regulation No 536/2014 required that participants in clinical trials represent the population groups (e.g., age and gender groups) that are likely to use the medicinal product investigated in the clinical trial. Noninclusion had to be justified. The regulation defined conditions under which pregnant and breastfeeding women could participate in clinical trials. Outcomes had to be analyzed and results presented by age groups and sex. [9, 10] FOR HUMAN USE (ICH) 2004: Based on the findings from three ICH Regions' surveys, the ICH took the position that the findings did not support the development of a separate ICH Guideline on women. The outcome of the surveys, including the review of existing ICH Guidelines and regional experiences, were reported in an ICH Considerations document and posted on the ICH website. in June 2009, the Considerations document was updated to include the reference to relevant new and revised ICH Guidelines and to reflect the recognized distinction between the concepts sex and gender. [11] The ICH holds that existing requirements in demographic (including gender) characterization, analysis, and assessment of the patient population are adequate to guide clinical trials. [ Sex and gender: Sex refers to the biological attributes of humans and animals, including anatomy, chromosomes, hormones, and gene expression. [12] Gender represents the socially constructed differences between girls/women and boys/men in roles and access to resources and power. Sex and gender interact with each other and with other health determinants. Biological sex-differences in pharmaceutical response: these are based on genetics, body size and fat distribution, reproductive systems, and concentrations of hormones, enzymes, and other pharmaceutical-target molecules in gut absorption, blood concentration, liver, and kidney clearance rates (pharmacokinetics and pharmacodynamics). [13, 14] For example, women have differences in pharmacokinetics linked to increased adverse drug reactions (ADRs) that are potentially caused by insufficient dosage adjustments. [14] Women have a 1.5-2 times higher plasma concentration as men for Zofran, a drug to prevent nausea and vomiting from chemotherapy and used in post-operative patients, which may call for lower dosing among women. [15] Men have higher concentrations of angiotensin-converting enzyme-2 (ACE2)-a therapeutic target for ACE-inhibitors in treating cardiovascular conditions. [16] Women-specific life course events that influence pharmaceutical response: menstrual cycles, pregnancy, breastfeeding, menopause also can produce physiological and biochemical changes that influence safety and efficacy profiles. Exogenous hormones, in the form of hormonal contraceptives or gender-affirming therapies, cause an increase in estrogen and/or progesterone levels, potentially influencing drug elimination. Women-differentiated safety and adverse drug reactions: women using rosiglitazone and pioglitazone for type-2 diabetes have a higher risk of fractures. Women using anti-arrhythmia medications such as quinidine are at an increased risk of torsades de pointes, a potentially fatal arrhythmia. Women are 1.5-1.7 times more likely to experience an adverse drug reaction (ADR) than men. [17] polatuzumab vedotin-piiq Understanding Sex Differences at FDA Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women Policy set to reduce gender inequality in biomedical studies Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Inclusion of Women in Clinical Trials During Drug Development Women in clinical trials: a review of policy development and health equity in the Canadian context Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences Health Products for Women. aem Sex and Gender in Medicines Regulation OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on clinical trials on medicinal products for human use Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Sex-related considerations in the conduct of clinical trials Canadian Institutes of Health Research Government of Canada. Science is better with sex and gender Sex differences in pharmacokinetics and pharmacodynamics Sex differences in pharmacokinetics predict adverse drug reactions in women Women in Clinical Drug Trials: United States Food and Drug Administration Update on Policies and Practices Circulating plasma concentrations of angiotensinconverting enzyme 2 in men and women with heart failure and effects of renin-angiotensinaldosterone inhibitors Do Women Have More Adverse Drug Reactions?